公开(公告)号：US20240327390A1

公开(公告)日：2024-10-03

申请号：US18659052

申请日：2024-05-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

CPC classification number: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I)




or a salt thereof,

wherein R1 is:





each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US12037324B2

公开(公告)日：2024-07-16

申请号：US17861809

申请日：2022-07-11

Applicant: Université de Montréal ,  Bristol-Myers Squibb Company

Inventor： Eldon Scott Priestley ,  Samuel Kaye Reznik ,  Edward H. Ruediger ,  James R. Gillard ,  Oz Scott Halpern ,  Wen Jiang ,  Jeremy Richter ,  Rejean Ruel ,  Sasmita Tripathy ,  Wu Yang ,  Xiaojun Zhang

IPC: C07D401/14 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P9/04 ,  C07D233/90 ,  C07D235/26 ,  C07D239/20 ,  C07D257/04 ,  C07D271/07 ,  C07D401/10 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/10

CPC classification number: C07D401/14 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P9/04 ,  C07D233/90 ,  C07D235/26 ,  C07D239/20 ,  C07D257/04 ,  C07D271/07 ,  C07D401/10 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/10

Abstract: The present invention provides compounds of Formula (I):




wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

公开(公告)号：US20230242535A1

公开(公告)日：2023-08-03

申请号：US17902618

申请日：2022-09-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  UNIVERSITÉ DE MONTRÉAL

Inventor： Jacques Banville ,  Roger Rémillard ,  Edward H. Ruediger ,  Daniel H. Deon ,  Marc Gagnon ,  Laurence Dubé ,  Julia Guy ,  Eldon Scott Priestley ,  Shoshana L. Posy ,  Brad D. Maxwell ,  Pancras C. Wong ,  R. Michael Lawrence ,  Michael M. Miller

IPC: C07D487/04 ,  A61K31/454 ,  A61K31/5386 ,  A61K31/496 ,  A61K45/06 ,  C07B59/00 ,  A61K31/4439 ,  A61K31/5025 ,  A61K31/497 ,  A61K31/435 ,  A61K51/04 ,  A61K31/55 ,  C07D519/00 ,  A61K31/553 ,  A61K31/5377 ,  A61K31/433 ,  C07D513/04 ,  A61K31/541

CPC classification number: C07D487/04 ,  A61K31/55 ,  A61K31/433 ,  A61K31/435 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/541 ,  A61K31/553 ,  A61K31/4439 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/5386 ,  A61K45/06 ,  A61K51/0453 ,  C07B59/002 ,  C07D513/04 ,  C07D519/00 ,  C07B2200/05

Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

公开(公告)号：US10822343B2

公开(公告)日：2020-11-03

申请号：US16538917

申请日：2019-08-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  UNIVERSITÉ DE MONTRÉAL

Inventor： Jacques Banville ,  Roger Remillard ,  Edward H. Ruediger ,  Daniel H. Deon ,  Marc Gagnon ,  Laurence Dube ,  Julia Guy ,  Eldon Scott Priestley ,  Shoshana L. Posy ,  Brad D. Maxwell ,  Pancras C. Wong ,  R. Michael Lawrence ,  Michael M. Miller

IPC: C07D487/04 ,  A61K45/06 ,  C07D519/00 ,  C07D513/04 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/553 ,  A61K31/435 ,  A61K31/5386 ,  A61K31/55 ,  A61K51/04 ,  C07B59/00

Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

公开(公告)号：US20190248769A1

公开(公告)日：2019-08-15

申请号：US16344823

申请日：2017-11-02

Applicant: Bristol-Myers Squibb Company

Inventor： Prashantha Gunaga ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Manoranjan Panda ,  Navnath Dnyanoba Yadav ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  A61P9/12 ,  A61P9/04 ,  A61P13/02 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20180346453A1

公开(公告)日：2018-12-06

申请号：US15993683

申请日：2018-05-31

Applicant: Bristol-Myers Squibb Company

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D417/14 ,  C07D413/14

CPC classification number: C07D413/14 ,  C07D405/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is: each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US12060347B2

公开(公告)日：2024-08-13

申请号：US17123265

申请日：2020-12-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xiaojun Zhang ,  Eldon Scott Priestley ,  J. Alex Bates ,  Oz Scott Halpern ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D417/04 ,  A61P7/04 ,  A61P9/10 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04 ,  C07D519/00

CPC classification number: C07D417/04 ,  A61P7/04 ,  A61P9/10 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I) to (VIII):




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US20210163465A1

公开(公告)日：2021-06-03

申请号：US17123265

申请日：2020-12-16

Applicant: Bristol-Myers Squibb Company

Inventor： Xiaojun Zhang ,  Eldon Scott Priestley ,  J. Alex Bates ,  Oz Scott Halpern ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D417/04 ,  A61P7/04 ,  A61P9/10 ,  C07D405/04 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04 ,  C07D519/00 ,  C07D403/04

Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US20200339550A1

公开(公告)日：2020-10-29

申请号：US16928079

申请日：2020-07-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is: each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US10428077B2

公开(公告)日：2019-10-01

申请号：US16020043

申请日：2018-06-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  UNIVERSITE DE MONTREAL

Inventor： Jacques Banville ,  Roger Remillard ,  Edward H. Ruediger ,  Daniel H. Deon ,  Marc Gagnon ,  Laurence Dube ,  Julia Guy ,  Eldon Scott Priestley ,  Shoshana L. Posy ,  Brad D. Maxwell ,  Pancras C. Wong ,  R. Michael Lawrence ,  Michael M. Miller

IPC: C07D487/04 ,  C07D513/04 ,  C07D519/00 ,  A61K45/06 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/553 ,  A61K31/435 ,  A61K31/5386 ,  A61K31/55 ,  A61K51/04 ,  C07B59/00

Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.